IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells

[1]  J. Galon,et al.  Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. , 2015, Cancer research.

[2]  J. Taube,et al.  Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade , 2015, Clinical Cancer Research.

[3]  K. Okuno,et al.  Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. , 2014, Immunology letters.

[4]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[5]  J. Machiels,et al.  A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[6]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[7]  G. Coukos,et al.  Deciphering and reversing tumor immune suppression. , 2013, Immunity.

[8]  J. Banchereau,et al.  Dendritic-cell-based therapeutic cancer vaccines. , 2013, Immunity.

[9]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[10]  P. Sonneveld,et al.  A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma , 2013, British journal of haematology.

[11]  J. Furuse,et al.  Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.

[12]  S. Terada,et al.  The Key Role of IL-6–Arginase Cascade for Inducing Dendritic Cell–Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice , 2013, The Journal of Immunology.

[13]  S. Terada,et al.  Anti‐IL‐6 receptor mAb eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses , 2012, European journal of immunology.

[14]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[15]  Jae Hyuk Lee,et al.  Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. , 2012, Archives of surgery.

[16]  J. Banchereau,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[17]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[18]  T. Sasada,et al.  Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. , 2012, Experimental and therapeutic medicine.

[19]  S. Todo,et al.  First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen , 2012, Cancer science.

[20]  R. Edwards,et al.  Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.

[21]  E. Celis,et al.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer , 2011, Journal of Translational Medicine.

[22]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[23]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[24]  M. Ilyas,et al.  Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer , 2010, Gut.

[25]  H. Knüpfer,et al.  Serum interleukin-6 levels in colorectal cancer patients—a summary of published results , 2010, International Journal of Colorectal Disease.

[26]  V. Torri,et al.  CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. , 2009, The Lancet. Oncology.

[27]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[28]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[29]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[30]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[31]  T. Hirano,et al.  IL-6-STAT3 Controls Intracellular MHC Class II αβ Dimer Level through Cathepsin S Activity in Dendritic Cells , 2005 .

[32]  C. Jobin,et al.  STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells , 2005 .

[33]  T. Hirano,et al.  IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation1 , 2004, The Journal of Immunology.

[34]  R. Steinman,et al.  Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.

[35]  G. Feldman,et al.  STAT4 serine phosphorylation is critical for IL-12-induced IFN-γ production but not for cell proliferation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Harizi,et al.  Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. , 2001, Cellular immunology.

[37]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[38]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[39]  P. Kalinski,et al.  IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. , 1997, Journal of immunology.

[40]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[41]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[42]  G. Mazzolini,et al.  [Dendritic cell-based therapeutic cancer vaccines]. , 2016, Medicina.

[43]  Sven Malchow,et al.  Basic principles of tumor-associated regulatory T cell biology. , 2013, Trends in immunology.

[44]  N. Gupta,et al.  Effect of standard anthracycline based neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma breast - a prospective study. , 2012, International journal of surgery.

[45]  J. Bono,et al.  Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.